ArticleBMC pulmonary medicine2026
Serum desmosine served as a biomarker for severity and prognosis in COVID-19 patients.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundDesmosine exerts a vital role as a cross-linking molecule integrate into a three-dimensional elastin network. After degradation of mature elastin, desmosine is released and enters into the circulatory system. The purpose was to estimate the association between serum desmosine level and Coronavirus disease 2019 (COVID-19) patients.
methodsAll 333 COVID-19 patients were enrolled and regarded as the training cohort, and 150 cases were used for completely independent validation cohort. Serum specimens were collected on the day of admission. The level of serum desmosine was determined by enzyme-linked immunosorbent assay (ELISA).
resultsSerum desmosine level on the day of admission gradually increased with elevating severity scores among COVID-19 patients. Spearman correlation analysis unveiled the close relationships between serum desmosine level and clinical parameters, such as liver function, renal function, myocardial enzymes, and inflammatory cytokines. The training cohort and external validation cohort revealed that serum desmosine level was positively associated with severity scores by multivariable linear regression analyses. Multivariable logistic regression models found that higher serum desmosine concentration on admission elevated the risks of mechanical ventilation, vasoactive agent use, ICU admission, and death during hospitalization. A receiver operating characteristic (ROC) curve analysis demonstrated the excellent discrimination for the poor prognosis of serum desmosine concentration by the training set and validation set.
conclusionsBaseline serum desmosine level was positively associated with disease severity scores and worse clinical outcomes among COVID-19 patients during hospitalization, substantializing that serum desmosine might serve as a biomarker for discriminating the severity and prognosis in COVID-19 patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.